Management of the extravasation of anti-neoplastic agents
- 26 February 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 23 (5), 1459-1471
- https://doi.org/10.1007/s00520-015-2635-7
Abstract
Extravasation is a potentially severe complication that can occur during the administration of chemotherapy. The scarcity of evidence available makes it difficult to develop an optimal management scheme. The purpose of this guideline is to review the relevant scientific literature on the prevention, management, and treatment of extravasation occurring during the administration of chemotherapy to cancer patients. A scientific literature review was conducted using the PubMed search tool. The period covered was from database inception to April 2014, inclusively. Since the literature on extravasation treatment is often empirical, anecdotal, and controversial, the review also identified clinical practice guidelines and expert consensuses published by relevant international organizations and cancer agencies. Identification of potential risk factors and preventive measures can reduce the risk of extravasation. Recognition and management of symptoms are crucial in patients with this complication. Provision of adequate instruction to personnel responsible for administering chemotherapy and to patients on recognizing symptoms, preventing, and managing extravasation is essential. Extravasation can be treated with dry warm or cold compresses and various antidotes such as dimethyl sulfoxide, dexrazoxane, hyaluronidase, or sodium thiosulfate, depending on the agent that has caused extravasation. Patient monitoring to assess the progression or regression of symptoms and to thus take the appropriate measures is necessary. Several strategies must be established to ensure that extravasation is recognized and properly managed. Given the evidence available at this time, the Comité de l’évolution des pratiques en oncologie (CEPO) has made recommendations for clinical practice in Quebec.Keywords
This publication has 51 references indexed in Scilit:
- Management of Cytotoxic Extravasation - ASORS Expert Opinion for Diagnosis, Prevention and TreatmentOncology Research and Treatment, 2013
- Chemotherapy Extravasations: Prevention, Identification, Management, and DocumentationClinical Journal of Oncology Nursing, 2013
- Savene® (dexrazoxane) use in clinical practiceSupportive Care in Cancer, 2012
- Vesicant Extravasation Part II: Evidence-Based Management and Continuing ControversiesOncology Nursing Forum, 2006
- Vesicant Extravasation Part I: Mechanisms, Pathogenesis, and Nursing Care to Reduce RiskOncology Nursing Forum, 2006
- Extravasations of OxaliplatinJournal of Clinical Oncology, 2003
- Evaluation and treatment of chemotherapy extravasation injuriesJournal of Pediatric Oncology Nursing, 2000
- DexrazoxaneDrugs, 1998
- Prevention and Management of Extravasation of Cytotoxic DrugsDrug Safety, 1995
- Hyaluronidase as an antidote to extravasation ofVinca alkaloids: Clinical resultsZeitschrift für Krebsforschung und Klinische Onkologie, 1994